Navigation Links
Shire Engages Palio
Date:1/22/2008

Palio Named Agency of Record for FOSRENOL(R)

SARATOGA SPRINGS, N.Y., Jan. 22 /PRNewswire-FirstCall/ -- Palio, an inVentiv Health (Nasdaq: VTIV) company, is pleased to announce that Shire Pharmaceuticals (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) has engaged Palio as agency of record to lead the professional advertising and promotion for Shire's FOSRENOL, which is part of Shire's renal business unit.

"We are excited to put our team's experience and insight to work on behalf of this important product. And, we look forward to becoming a true marketing partner with Shire's FOSRENOL team," said Mike Myers, president of Palio.

Shire is a global specialty biopharmaceutical company with US operations headquartered in Chester County, Pennsylvania, just outside of Philadelphia.

"Palio's initial concept work on FOSRENOL demonstrated a level of strategic thinking and creativity that was unmatched. Their focus on the brand, their medical insight, and their commitment to our business has raised our expectations," said Joe Schlitz, vice president, US commercial lead, renal business unit, Shire Pharmaceuticals. "At Shire, our mission is to develop and market medicines that improve the quality of life for patients and their caregivers. We're looking forward to working with Palio in achieving our vision."

Palio, a full-spectrum advertising and communications agency headquartered in Saratoga Springs, NY, excels in brand creation that changes the way people think with execution that will Never be forgotten(SM). For more information on Palio, visit http://www.palio.com.

About SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), and gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent that opportunities arise through acquisitions. Shire's in-licensing, merger, and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the United States or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company's Web site: http://www.shire.com.

About inVentiv Health

inVentiv Health, Inc. (Nasdaq: VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 275 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.


'/>"/>
SOURCE Palio
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... The latest generation of ... of sample prep for metals digestion—the addition of acids and reagents. The accessory ... The system is ideal for any laboratory performing their own unique metals digestion ...
(Date:9/19/2017)... , ... September 19, 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. ... PhD in Riordan’s new book "Stem Cell Therapy: A Rising Tide". Dr. Harman and ... They bonded over an interest in the potential of stem cell therapy and a ...
(Date:9/19/2017)... -- ValGenesis Inc., the global leader in Enterprise Validation ... strategic partnership with VTI Life Sciences (VTI). This partnership ... the latest technology available in the ValGenesis VLMS system. ... and cost-effective validation services using ValGenesis VLMS. VTI will ... system. The partnership ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... Financial Services (NYS DFS) cybersecurity regulations have transitioned into full force ... organizations operating in the state (“Covered Entities”) to conduct an annual, professional, ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):